Your browser doesn't support javascript.
loading
[Treatment mapping of lower urinary tract symptoms due to benign prostatic hyperplasia-an analysis of the Governing Body of German Prostate Centers]. / Versorgungsabbild des benignen Prostatasyndroms ­ eine Analyse des Dachverbandes der Prostatazentren Deutschlands (DVPZ) e. V.
Herden, J; Ebert, T; Schlager, D; Pretzer, J; Zumbé, J; Sommerfeld, H-J; Schafhauser, W; Kriegmair, M; Garcia Schürmann, M; Distler, F; Baur, H; Oberpenning, F; Reimann, M; Schmidt, S; Laabs, S; Planz, B; Gronau, E; Platz, G; Göll, A; Buse, S; Jones, J; Haupt, G; Waldner, M; Heidenreich, A; Khaljani, E; Rübben, H; Schultze-Seemann, W; Weib, P.
Afiliação
  • Herden J; Dachverband der Prostatazentren Deutschlands e. V., Berlin, Deutschland. jan.herden@uk-koeln.de.
  • Ebert T; Prostatazentrum Köln, Campus Universitätsklinikum, Kerpener Str. 62, 50937, Köln, Deutschland. jan.herden@uk-koeln.de.
  • Schlager D; Dachverband der Prostatazentren Deutschlands e. V., Berlin, Deutschland.
  • Pretzer J; Prostatazentrum Metropolregion Nürnberg, Nürnberg, Deutschland.
  • Zumbé J; Prostatazentrum Freiburg, Freiburg, Deutschland.
  • Sommerfeld HJ; Berliner Prostatazentrum, Berlin, Deutschland.
  • Schafhauser W; Dachverband der Prostatazentren Deutschlands e. V., Berlin, Deutschland.
  • Kriegmair M; Prostatazentrum Leverkusen, Leverkusen, Deutschland.
  • Garcia Schürmann M; Prostatazentrum Marl, Marl, Deutschland.
  • Distler F; Prostatazentrum Hochfranken-Fichtelgebirge, Marktredwitz, Deutschland.
  • Baur H; Prostatazentrum Urologie Centrum München, Planegg, Deutschland.
  • Oberpenning F; Prostatazentrum Niederrhein, Wesel, Deutschland.
  • Reimann M; Prostatazentrum Nürnberg-Mittelfranken, Nürnberg, Deutschland.
  • Schmidt S; Prostatazentrum Nymphenburg, München, Deutschland.
  • Laabs S; Prostatazentrum Bocholt, Bocholt, Deutschland.
  • Planz B; Prostatazentrum Moers, Moers, Deutschland.
  • Gronau E; Prostatazentrum Rhein-Ruhr, Oberhausen, Deutschland.
  • Platz G; Prostatazentrum Elbe-Weser, Stade, Deutschland.
  • Göll A; Prostatazentrum Emscher-Lippe, Gladbeck, Deutschland.
  • Buse S; Prostatazentrum Münsterland, Münster, Deutschland.
  • Jones J; Prostatazentrum Mainspitze, Rüsselsheim, Deutschland.
  • Haupt G; Dachverband der Prostatazentren Deutschlands e. V., Berlin, Deutschland.
  • Waldner M; Prostatazentrum Alfred Krupp Krankenhaus, Essen, Deutschland.
  • Heidenreich A; Prostatazentrum Alfred Krupp Krankenhaus, Essen, Deutschland.
  • Khaljani E; Prostatazentrum Hochtaunus, Bad Homburg, Deutschland.
  • Rübben H; Prostatazentrum Speyer, Speyer, Deutschland.
  • Schultze-Seemann W; Prostatazentrum Köln, Campus Hohenlind, Köln, Deutschland.
  • Weib P; Prostatazentrum Köln, Campus Universitätsklinikum, Kerpener Str. 62, 50937, Köln, Deutschland.
Urologe A ; 59(9): 1082-1091, 2020 Sep.
Article em De | MEDLINE | ID: mdl-32274545
ABSTRACT

BACKGROUND:

Due to the high incidence and demographic development, there is an urgent need for healthcare research data on lower urinary tract symptoms due to benign prostatic hyperplasia (LTUS/BPH). Since 2005 the Governing Body of German Prostate Centers (DVPZ) has been collecting data from 22 prostate centers in order to determine the quality and type of cross-sectoral care in particular for LUTS/BPH patients.

OBJECTIVES:

Presentation of the DVPZ database in general, as well as an investigation of treatment patterns for medical and instrumental therapies. MATERIALS AND

METHODS:

The analysis is based on UroCloud data sets from 30 November 2017. In the UroCloud data on diagnostics, therapy and course of disease are recorded in a web-based manner.

RESULTS:

A total of 29,555 therapies were documented for 18,299 patients (1.6/patient), divided into 48.5% instrumental, 29.2% medical treatment, and 18.0% "wait and see" (in 4.3% no assignment was possible). Patients treated with an instrumental therapy were oldest (median 72 years, interquartile range 66-77), had the largest prostate volumes (50 ml, 35-75 ml), and were mostly bothered by symptoms (International Prostate Symptom Score = 19/4). The majority of patients under medical treatment received alphablockers (56%); phytotherapeutics were used least frequently (3%). Instrumental therapies are dominated by transurethral resection (TUR) of the prostate (60.0%), open prostatectomy (9.4%) and laser therapy (5.0%), with laser therapy having the shortest hospital stay (5 days) and the lowest transfusion and re-intervention rates (1.0% and 4.6%, respectively).

CONCLUSIONS:

The DVPZ certificate covers the complete spectrum of cross-sectoral care for LUTS/BPH patients and documents the use of the various therapies as well as their application and effectiveness in the daily routine setting.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hiperplasia Prostática / Antagonistas Adrenérgicos alfa / Ressecção Transuretral da Próstata / Terapia a Laser / Sintomas do Trato Urinário Inferior Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies Limite: Aged / Humans / Male País/Região como assunto: Europa Idioma: De Revista: Urologe A Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hiperplasia Prostática / Antagonistas Adrenérgicos alfa / Ressecção Transuretral da Próstata / Terapia a Laser / Sintomas do Trato Urinário Inferior Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies Limite: Aged / Humans / Male País/Região como assunto: Europa Idioma: De Revista: Urologe A Ano de publicação: 2020 Tipo de documento: Article